Sheila Rege
Mirion TechnologiesAbout Sheila Rege
Dr. Sheila Rege, age 59, is an independent director of Mirion Technologies and a board‑certified radiation oncologist; she joined Mirion’s Board in September 2022 and serves on the Audit and Compensation Committees . She holds a B.A. from UC Berkeley and an M.D. from UCLA, and earned the NACD CERT Certificate in Cyber‑Risk Oversight, aligning with the Board’s cybersecurity risk governance .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Northwest Cancer Clinic | Founder; former CEO | Opened 2012 | Built radiation oncology and nuclear medicine provider; 30+ years in nuclear medicine/radiation oncology cited |
| Physicians Insurance (mutual company) | Director | 2007–2019 | Chair, Nominating; Member, Compensation, Executive, CEO Succession |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Washington State University | Faculty member | Not disclosed | Academic engagement in radiation oncology context |
| Public company boards | None disclosed | — | — |
Board Governance
| Committee | Role | Chair | Meetings (2024) | Attendance |
|---|---|---|---|---|
| Audit | Member | Steven W. Etzel | 8 | Each director attended ≥75% of Board and committee meetings |
| Compensation | Member | Robert A. Cascella | 6 | Each director attended ≥75% of Board and committee meetings |
- Independence: Rege is independent under NYSE rules; in 2025 all directors other than the CEO are independent .
- Cyber oversight: Rege (and Audit Chair Etzel and Nominating Chair Kuo) hold NACD CERT cybersecurity oversight credentials; management provides quarterly cybersecurity updates to Audit Committee .
- Board composition: Diverse skills/experiences; Rege self‑identifies as Asian Heritage .
- Lead Independent Director: Kenneth C. Bockhorst, with defined responsibilities for executive sessions, agendas, and liaison functions .
Fixed Compensation
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Fees Earned or Paid in Cash ($) | $22,059 | $76,500 | $76,500 |
| Stock Awards ($) | $69,669 | $93,495 | $140,000 |
| Total ($) | $88,794 | $169,995 | $216,500 |
- Director compensation program (2024, through June 4, 2024 amendment): Board retainer $76,500; Lead Independent Director $25,000; committee chair fees $10,000 each (Audit, Compensation, Nominating/Gov) .
Performance Compensation
| RSUs Outstanding (Aggregate) | As of Dec 31, 2022 | As of Dec 31, 2023 | As of Dec 31, 2024 |
|---|---|---|---|
| Shares underlying RSUs | 6,112 | 5,925 | 6,750 |
- Annual director equity grants are RSUs with grant‑date fair values computed under ASC 718; no performance metrics are disclosed for director equity awards .
Other Directorships & Interlocks
| Organization | Type | Role | Tenure | Notes |
|---|---|---|---|---|
| Physicians Insurance | Private (mutual) | Director | 2007–2019 | Chair Nom.; Member Comp., Exec., CEO Succession |
- Compensation Committee interlocks: None disclosed; no Mirion executive officers served on boards/comp committees of other entities with reciprocal service by Mirion executives .
Expertise & Qualifications
- Radiation oncology and nuclear medicine domain expertise; founded Northwest Cancer Clinic .
- Cyber‑risk oversight certification (NACD CERT) aligned with Audit Committee risk oversight .
- Recognitions: ACRO 2023 Gold Medal; AMA Inspiration Award (2021); Private Company Boardroom 2022 “Directors to Watch”; ACRO 2022 Sucha Asbell Mentorship Award .
- Diversity: Female; Asian Heritage .
Equity Ownership
| Item | Date/As of | Amount/Detail |
|---|---|---|
| Beneficial ownership of Class A common | Mar 31, 2023 | 6,111 shares; 0.0028% of 217,687,852 Class A shares outstanding (computed from 6,111 and 217,687,852) |
| Form 3 (initial statement) | Sept 20, 2022 | “No securities are beneficially owned” at appointment |
| RSUs outstanding (see above) | Dec 31, 2022/2023/2024 | 6,112; 5,925; 6,750 |
Note: No pledging or hedging disclosures specific to Rege were found in retrieved documents; stock ownership guideline details for directors were not disclosed in the cited Mirion proxies we accessed.
Governance Assessment
-
Signals of effectiveness and alignment:
- Dual membership on Audit and Compensation Committees positions Rege at the center of financial reporting integrity and pay‑for‑performance oversight; Audit met 8 times and Compensation 6 times in 2024, indicating active committee cadence .
- Formal cybersecurity oversight credentials (NACD CERT) augment Board risk governance in a business exposed to regulated nuclear/medical markets .
- Independence affirmed under NYSE rules; Board structure includes a Lead Independent Director and regular executive sessions—positive governance architecture .
- Equity alignment via annual RSU grants ($140,000 grant‑date value in 2024) complements cash retainers .
-
Potential red flags and mitigants:
- Low absolute ownership: 6,111 Class A shares as of March 31, 2023 (≈0.0028% of outstanding), typical for external directors but modest “skin‑in‑the‑game” in absolute terms .
- Related‑party exposure: None disclosed upon appointment; no Item 404(a) related‑party transactions noted, reducing conflict risk .
- Attendance: Company states each director met ≥75% attendance in 2024; while compliant, proxies do not provide individual attendance breakdowns .
-
Overall: Rege brings deep domain expertise in radiation oncology with demonstrable committee engagement, independence, and cyber oversight credentials—factors that should support investor confidence in Board risk and compensation oversight .